KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other financing activities (2020 - 2022)

Halozyme Therapeutics (HALO) has disclosed Other financing activities for 3 consecutive years, with $639000.0 as the latest value for Q4 2022.

  • On a quarterly basis, Other financing activities changed N/A to $639000.0 in Q4 2022 year-over-year; TTM through Dec 2023 was $6.6 million, a 0.0% change, with the full-year FY2025 number at $4.9 million, changed N/A from a year prior.
  • Other financing activities was $639000.0 for Q4 2022 at Halozyme Therapeutics, down from $6.0 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $6.0 million in Q2 2022 to a low of -$68000.0 in Q2 2020.
  • A 3-year average of $1.2 million and a median of $234000.0 in 2020 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: soared 135.29% in 2021, then surged 24912.5% in 2022.
  • Halozyme Therapeutics' Other financing activities stood at -$68000.0 in 2020, then skyrocketed by 135.29% to $24000.0 in 2021, then skyrocketed by 2562.5% to $639000.0 in 2022.
  • Per Business Quant, the three most recent readings for HALO's Other financing activities are $639000.0 (Q4 2022), $6.0 million (Q2 2022), and $24000.0 (Q2 2021).